Apyx Medical Corporation

177 articles with Apyx Medical Corporation

• Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2020 Financial Results on November 9, 2020

  10/1/2020

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the third quarter of fiscal year 2020 will be released before the market opens on Monday, November 9.

• Apyx Medical Corporation to Participate in Upcoming Investor Conferences in September

  8/31/2020

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences

• Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020

  6/25/2020

  Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020

• Apyx Medical Corporation Announces Regulatory Clearance to Market and Sell its Helium Plasma Technology Products in Five New Countries

  6/22/2020

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that the Company has obtained regulatory approval to market and sell its Helium Plasma Technology products in five new countries: Australia, Brazil, Israel, Taiwan and Thailand.

• Apyx Medical Corporation Reports First Quarter 2020 Financial Results

  5/11/2020

  Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, reported financial results for its first quarter ended March 31, 2020.

• Apyx Medical Corporation to Release First Quarter of Fiscal Year 2020 Financial Results on May 11, 2020

  4/7/2020

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2020 will be released before the market opens on Monday, May 11. Management will host a

• Apyx Medical Corporation to Restate Previously Issued Financial Statements

  3/16/2020

  Apyx Medical Corporation announced it will be restating its previously issued consolidated financial statements for the twelve months ended December, 31 2018 and the quarterly statements for the three and nine months ended September 30, 2018 and three months ended March 31, 2019.

• Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 16, 2020

  2/5/2020

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2019 will be released after the market closes on Monday, March 16.

• Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results

  1/13/2020

  Apyx Medical Corporation reported preliminary revenue results for the full year and fourth quarter ended December 31, 2019.

• Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion® Technology in Dermal Resurfacing Procedures

  12/3/2019

  Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and as J-Plasma® in the hospital surgical market, announced today that it has initiated subject enrollment in a U.S. Investigational Device Exemption (IDE) clinical study evaluating the use of its Renuvion technology in dermal resurfacing procedures.

• Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook

  11/11/2019

  Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, reported financial results for its third quarter ended September 30, 2019.

• CORRECTING and REPLACING Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook

  11/11/2019

  In the "2019 Financial Outlook" section, the fifth bulleted item should read: GAAP net loss in the range of $20.3 million to $19.8 million.

• Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November and December

  11/4/2019

  Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and as J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences

• Apyx Medical Corporation Announces Subject Enrollment Initiated in Study Evaluating the Use of Renuvion® Technology in Skin Laxity Procedures in the Neck and Submental Region

  10/14/2019

  Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion®

• Apyx Medical Corporation Receives 510(k) Clearance for the Apyx Plasma/RF Handpiece

  10/14/2019

  Apyx Medical Corporation announced that it received U.S. Food and Drug Administration 510 clearance to market and sell the Apyx Plasma/RF Handpiece, a new addition to the Renuvion product family.

• Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2019 Financial Results on November 11, 2019

  9/24/2019

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), today announced that financial results for the third quarter of fiscal year 2019 will be released after the market closes on Monday, November 11.

• Apyx Medical Corporation to Participate in Upcoming Investor Conferences in September and October

  8/22/2019

  Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences:

• Apyx Medical Corporation Reports Second Quarter and First Half of 2019 Financial Results and Updates Fiscal Year 2019 Outlook

  8/7/2019

  Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2019.

• Apyx Medical Corporation Announces Appointment of Minnie Baylor-Henry to the Company’s Board of Directors

  8/6/2019

  Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Minnie Baylor-Henry to the Board of Directors, effective August 1, 2019

• Apyx Medical Corporation Receives 510(k) Clearance for Next-Generation J-Plasma® Precise Handpiece Designed for Laparoscopic Surgery

  8/5/2019

  The Company’s J-Plasma handpieces are indicated for cutting, coagulation and ablation of soft tissue during open and laparoscopic surgical procedures.